Genprex, Inc.

Equities

GNPX

US3724462037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
1.885 ^USD	-4.31%		-6.68%	-79.51%

15/05	Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
14/05	Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	CI

GENPREX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 29, 2021 at 03:02 am IST

Item 8.01 Other Events.

On January 28, 2021, Genprex, Inc. (the "Company") issued a shareholder letter and fact sheet providing recent updates on regulatory, clinical, operational, and business developments. The full text of the shareholder letter and fact sheet is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
Number       Description
 99.1         Shareholder Letter and Fact Sheet dated January 2021 issued by
            Genprex, Inc.

--------------------------------------------------------------------------------

Latest news about Genprex, Inc.

Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	14/05	CI
Genprex, Inc. Appoints Jose A. Moreno Toscano as Chairman of the Board of Directors	13/05	CI
Genprex, Inc Announces Executive Changes	09/05	CI
Genprex, Inc Announces Executive Changes	09/05	CI
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	03/04	CI
Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System	02/04	CI
Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target	25/03	MT
Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants	23/03	MT
Genprex Launches $6.5 Million Securities Offering; Shares Fall	19/03	MT
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers	12/03	MT
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	12/03	CI
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	07/02	CI
Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer	05/02	CI
Genprex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
North American Morning Briefing : Investors Weigh -2-	10/11	DJ
Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics	04/23/04	CI
North American Morning Briefing : Nasdaq Futures -2-	24/23/24	DJ
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs	22/23/22	CI
Genprex, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/23/21	CI
Genprex's Small-Cell Lung Cancer Treatment Gets FDA Orphan Drug Designation; Shares Rise	10/23/10	MT
Genprex Closes $7.5 Million Offering	22/23/22	MT
Genprex to Raise $7.5 Million From Registered Direct Offering; Shares Slip	19/23/19	MT
Genprex Licenses Diabetes Gene Therapy From University of Pittsburgh	18/23/18	MT

Chart Genprex, Inc.

Duration

Period

More charts

Company Profile

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Companyâs technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Companyâs lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.885 USD

Average target price

165 USD

Spread / Average Target

+8,653.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENPREX, INC.	-79.51%	3.95M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs